"LIPID_ID"	"CLASSIFICA"	"CHEM_NA"	"COMMON_NA"	"SYMBOL"	"GROUP_NA"	"MOL_FORMULA"	"FORMULA_C"	"FORMULA_H"	"FORMULA_O"	"FORMULA_N"	"FORMULA_P"	"FORMULA_S"	"MOL_WT"	"STR_1"	"STR_2"	"STR_3"	"STR_4"	"STR_5"	"STR_6"	"STR_7"	"STR_8"	"STR_9"	"STR_10"	"STR_11"	"REF_STR"	"MELT_PT"	"BOIL_PT"	"OPT_ROT"	"REFRA_IND"	"DENSITY"	"SOLUBILITY"	"REF_PRP"	"UV_SPEC"	"IR_SPEC"	"NMR_SPEC"	"MS_SPEC"	"NOTE_SPEC"	"REF_SPC"	"SOURCE"	"REF_SOU"	"BIOL_ACTIV"	"REF_BA"	"NOTE"	"REF_NOTE"
"PR0001"	13.00	"7-[3(R)-HYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL-5-OXOCYCLOPENTAN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN E2"	"PGE2"	"OUB"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"      O                                                   (REF:001)"	"      �ｾ�ﾄ＼�ｧ／＼／＼"	"    ／�ｻ              COOH"	"    ＼�ｺ"	"    �ﾃ  �ﾔ�ｷ＼／＼／＼／"	"     OH       �ﾂ"	"              OH"					"001/"	"65-66 (002)"		"[α]26/D=-61.0(C 1.0,TETRAHYDROFURAN)(002)"			"SOL.IN ETHYL ACETATE,THF,CHLOROFORM(003/007) STABILITIES:中性付近の水溶液で安定． 酸性下あるいはアルカリ性下ではPGB2に分解する(005/006)．"	"002/003/007/005/006/"		"d,l体: 3400,1710,970cm-1(004)"	"13C-NMR(CDCl3)(003): 214.71(C9),178.39(C1),136.62(C14),131.52(C13),130.91  (C5)126.69(C6),73.19(C15),72.13(C11),54.55(C12),53.51(C8),46.23(C10),37.00 (C16)33.56(C2),31.73(C18),26.47(C4),25.20(C7,17),24.60(C3),22.64(C19),14.04
1H NMR(CDCl3)(003): δ5.67(d"	"d,l体: 334(M+/-18),316,298,190 (004)"		"004/003/"	"・動物の精嚢，子宮，卵巣，臍帯，胃腸管，腎，副腎，膵，気管，肺，骨，白血球 ，脳，末梢神経，甲状腺などにその合成酵素が存在し，刺激に応じて新規に合成さ れる．・精液の中には既に合成されたものが蓄積している．"		"・子宮筋収縮，胃腸管収縮，血管拡張，気管支拡張，利尿，発熱，脂肪分解抑制，胃酸分泌抑制，骨吸収，免疫抑制 ・PGE2受容体を介して生物作用を発現するものと考えられる．"			
"PR0002"	13.00	"7-[3(R),5(S)-DIHYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL-CYCLOPENTAN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN F2α"	"PGF2α"	"OUB"	"C20H34O5"	20.00	34.00	5.00	0.00	0.00	0.00	354.00	"       OH                                                 (REF:008)"	"       �ﾂ�ﾄ＼�ｧ／＼／＼"	"     ／�ｻ              COOH"	"     ＼�ｺ"	"       �ﾂ�ﾖ�ｷ＼�ｷ＼／＼／＼／"	"       OH      �ﾂ"	"               OH"					"008/"	"25-35 (009)"		"[α]25/D=23.8 (C=1,THF)  (002)"			"SOL. IN ETHYL ACETATE, ACETONE,DIETHYLETHER(006)  STABILITIES:中性およびアルカリ性の水溶液で安定(005)"	"009/002/006/005/"		"NEAT:3320,2640,1710,1295,1260,1245,1120,1080,1055,1025,975cm-1 (006)"	"d6 ACETONE:5.48(m,4H),4.05(m,3H),0.9(t,3H,20-CH3) (006)
13C-NMR(010):176.6(C1),135.0(C14),132.8(C5),129.1(C13 OR C6),128.9(C6 OR C13),77.2(C11),72.9(C15),71.8(C9),55.0(C12),49.9(C8),42,6(C10),36.8(C16),33.2(C2),31,5(C18),26.3(C4),25.1(C7),25.1(C17),24.5("	"354(M+),336,318,292,274,264(100),247,229,191,177,165,137,99,81,67(011)"		"006/010/011/"	"・動物の精嚢，子宮，卵巣，臍帯，胃腸管，腎，副腎，膵，気管，肺，脳，などにその合成酵素が存在し，刺激に応じて新規に生合成される ・精液の中には既に合成されたものが蓄積している．"		"・子宮筋収縮，胃腸管収縮，気管支収縮，黄体退縮，血管収縮  ・ＰＧＦ2α受容体を介して生物作用を発現するものと考えられる．"			
"PR0003"	13.00	"7-[5(S)-HYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-3-OXOCYCLOPENTAN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN D2"	"PGD2"	"OUB"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"      OH                                             (REF:012)"	"      �ﾂ�ﾄ＼�ｧ／＼／＼"	"    ／�ｻ              COOH"	"    ＼�ｺ"	"      �ｾ�ﾖ�ｷ＼／＼／＼／"	"      O       �ﾂ"	"              OH"					"012/"	"68 (012)"		"[α]20/D=9 (C2.11,THF)   (014)"			"SOL. IN ETHYL ACETATE,THF,CHLOROFORM  (014)"	"012/014/"		"(KBr) 3400-2500,1740,1700,975cm-1(012)"	"270MHz,CDCl3:δ5.63(dd,J=7 & 16Hz,1H,14-CH),5.43(dd,J=16 & 8.5Hz,1H,13-CH) 4.47(m,1H,9-CH),4.09(bq,J=7Hz,1H,15-CH),2.87(dd,J=12 & 8.5Hz,H1,12-CH),  2.45(m,2H,10-CH2),1.95(bm,1H,8-CH)  (013)"""	"334,316,246,245,191,190,161,55(014)"		"012/013/014/"	"・動物の脳，肺，脾，肥満細胞などにその合成酵素が存在し，刺激に応じて新規に生合成される．"		"・胃腸管収縮，気管支収縮，血小板凝集抑制，腫瘍細胞増殖抑制，睡眠誘発，体温下降．ＰＧＤ2受容体を介して生物作用を発現するものと考えられる．"			
"PR0004"	13.00	"5(Z)-[7(R)-HYDROXY-6(R)-(3(S)-HYDROXYOCTEN-1(E)-YL)-1(S),5(R)-2-OXABICYCLO [3.3.0]OCT-3-YLIDENEPENTANOIC ACID"	"PROSTAGLANDIN I2"	"PGI2"	"OUB"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"          ／＼／＼                                          (REF:015)"	"        �ｷ        COOH"	"    O �ｼ＼"	"    �ﾅ  �ﾄ"	"    ／�ｻ"	"    ＼�ｺ"	"    �ﾄ  �ﾖ�ｷ＼／＼／＼／"	"   OH         �ﾂ"	"              OH"		"     OH        �ﾞ"	"015/"			"[α]/D=78(C 0.8820,CHCl3)  (017)"			"STABILITIES:中性付近の水溶液中(37ﾟC)で,半減期約５分で分解して6-KETO-PGF1α になる．(018)"	"017/018/"		"METHYL ESTER: LIQUID MELT ν3370,1740,1695cm-1(017)"	"D2O GLYCINE BUFFER,pH10.4:δ5.60(m,2H,13,14-CH),4.66(m,1H,9-CH),4.39(t,1H, 5-CH),4.15(q,1H,15-CH),3.97(q,1H,11-CH),2.20(t,2H,2-CH2)(016)"	"495(M+/-CH3),479,439,423,349,327,323,315,313,199,17 11,15-BIS(TRIMETHYLSILYL)ETHER METHYLESTER (017)"		"017/016/"	"・動物の血管にその合成酵素が存在し，刺激に応じて新規に生合成される．"		"・血管拡張，血小板凝集抑制，胃酸分泌抑制．・ＰＧＩ2受容体を介して生物作用を発現すると考えられる．"			
"PR0005"	13.00	"7-[2(R)-(3(S)-HYDROPEROXY-1(E)-OCTENYL)-1(R),4(S)-5,6-DIOXABICYLO[2.2.1]-  HEPTAN-3(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN G2"	"PGG2"	"OUB"	"C20H32O6"	20.00	32.00	6.00	0.00	0.00	0.00	368.00	"   O                                         (REF:019)"	"   �ｵ�ﾅ  �ﾄ＼�ｧ／＼／＼"	"   �ｵ／�ｻ              COOH"	"   �ｵ＼�ｺ"	"   �ｵ�ﾄ  �ｿ�ｷ＼／＼／＼／"	"   O           �ﾂ"	"               OOH"					"019/"						"STABILITIES:中性付近の水溶液中(37ﾟC）で半減期約５分で分解してPGE2,PGD2,PGF212L-HYDROXY-5,8,10-HEPTADECATRIENOIC ACIDになる．(021)"	"021/"			"13C-NMR δ84.6(C15)(020)"			"020/"	"・動物の精嚢，胃腸管，血小板，肺など多くの動物組織で，プロスタグランジンとトロンボキサンの生合成の中間体として生成する．"		"・胃腸管収縮，気管支収縮，血管収縮，血小板凝集． ・トロンボキサンA2の受容体を介して生物作用を発現すると考えられる．"			
"PR0006"	13.00	"7-[2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-1(R),4(S)-5,6-DIOXABICYCLO[2.2.1]HEPTAN-3(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGALANDIN H2"	"PGH2"	"OUB"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"    O                                                (REF:019)"	"  �ｶ �ﾅ  �ﾄ＼�ｧ／＼／＼"	"  �ｶ ／�ｻ              COOH"	"  �ｶ ＼�ｺ"	"  �ｶ �ﾄ  �ｿ�ｷ＼／＼／＼／"	"    O          �ﾂ"	"               OH"					"019/"						"SOL. IN CHCl3,METHYL ENCHLORIDE,ETHYL ACETATE (022/023)  STABILITIES:中性付近の水溶液中(37ﾟC)で半減期約５分で分解してPGE2,PGD2,PGF2, 12-HYDROXY-5,8,10-HEPTADECATRIENOIC ACIDになる．(021)"	"022/023/021/"		"METHYL ESTERのCHARTが記載 (022)"	"1H-NMRのCHARTが記載(022)
13C-NMR(CD2Cl2)(023):178.5(C1),133.5,130,4,130,0,128.4,82,1,79,6(C9&C11),72.7(C15),50.4,48.2,42.4,37.0,33.1,31.7,26.9,26.3,25.1,24.5,22.7,14.0"	"15-TRIMETHYLSILYLETHER METHYLETHERのCHARTが記載(024)"		"022/023/024/"	"・動物の精嚢，胃腸管，血小板，肺など多くの動物組織でプロスタグランジンとトロンボキサンの生合成の中間体として生成する．"		"・胃腸管収縮，気管支収縮，血管収縮，血小板凝集． ・トロンボキサンA2の受容体を介して生物作用を発現すると考えられる．"			
"PR0007"	13.00	"5(S),12(R)-DIHYDROXYICOSA-6(Z),8(E),10(E),14(Z)-TETRAENOIC ACID"	"LEUKOTRIENE B4"	"LTB4"	"OUB"	"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	" H  OH         H  OH                                  (REF:025)"	"  �ﾅ�ﾑ          �ﾅ�ﾑ      COOH"	"  ／＼�ｷ＼�ｷ＼�ｧ／＼／＼／"	"�ｶ"	"  �ｸ／＼／＼／"							"025/"						"SOL. IN METHANOL (026)"	"026/"	"CH3OH:260(ε38,000), 270.5(ε50,000), 281(ε39,000)nm  (026)"		"250MHz,D2O δ6.45(m,1H,H-8),6.15(m,2H,H-9,10),6.0(m,1H,H-7),5.65(m,1H,H-11),5.40(m,1H,H-15),5.25(m,2H,H-6,14),4.60(H-5),4.05(m,1H,H-12),2.15(m,2H,H-13),2.00(m,1H,H-2),1.85(m,2H,H-16),1.35-1.60(m,4H,H-3,4),1.00-1.25(m,6H,H-17-19),0.70(m,3H,H-20)(027)"	"m/e 336,319,301  (028)"""		"026/028/"	"動物の白血球やマクロファージにその合成酵素が存在し，刺激に応じて新規に生合   成される．"		"・多形核白血球の活性化（走化作用，運動増加，凝集，脱顆粒，ｽｰﾊﾟｰｵｷｼﾄﾞｱﾆｵﾝ産生） ・ＬＴＢ4受容体を介して生物作用を発現すると考えられる．"			
"PR0008"	13.00	"5(S)-HYDROXY-6(R)-S-γ-GLUTAMYLCYSTENYLGLYCINYLICOSA-7(E),9(E),11(Z),14(Z)-TETRAENOIC ACID"	"LEUKOTRIENE C4"	"LTC4"	"OUB"	"C30H47O9N3S"	30.00	47.00	9.00	3.00	0.00	1.00	625.00	"                        OH H                           (REF:029)"	"                       �ﾒ�ﾄ      COOH"	"           �ｷ＼�ｷ＼�ｷ＼／＼／＼／    ／＼"	"           �ｵ        �ﾕ�ﾅ        CONH    COOH"	"           �ｵ        H   S �ｭ＼／"	"           �ｵ                �ﾄ�ﾐ          COOH"	"           �ｵ               H  NHCO＼／＼／"	"           ＼�ｧ／＼／＼／              �ﾄ�ﾐ"	"                                      H   NH2"			"029/"						"SOL. IN METHANOL (030)"	"030/"	"CH3OH: λmax 270(ε32,000),280(ε40,000),290(ε31,000)nm  (030)"			"CHARTが記載(031)"		"030/031/"	"動物の白血球，肥満細胞，マクロファージ，気管支，肺，消化管，膵，脳などにそ の合成酵素が存在し，刺激に応じて新規に生合成される．"		"・気管支収縮，気道粘液分泌，血管透過性亢進，血管収縮，腸管収縮，血管新生促   進，黄体形成ホルモン分泌．・ＬＴＣ4受容体を介して生物活性を発現すると考えられる．"			
"PR0009"	13.00	"5(S)-HYDROXY-6(R)-S-CYSTEINYLGLYCINYLICOSA-7(E),9(E),11(Z),14(Z)-TETRAENOIC ACID"	"LEUKOTRIENE D4"	"LTD4"	"OUB"	"C25H40O6N2S"	25.00	40.00	6.00	2.00	0.00	1.00	496.00	"                     OH H                                    (REF:032)"	"                    �ﾒ�ﾄ      COOH"	"        �ｴ＼�ｴ＼�ｴ＼／＼／＼／"	"        �ｵ        �ﾕ�ﾅ        CONH／＼"	"        �ｵ        H   S �ｭ＼／        COOH"	"        �ｵ                  �ﾗH"	"        ＼�ｧ／＼／＼／      NH2"					"032/"						"SOL. IN METHANOL  (032)"	"032/"	"λMEOH/max=270(ε32,000),280(ε40,000),290(ε31,000)nm  (033)"			"N-ACETYL,5-TRIMETHYLSILYL ETHER DIMETHYL ESTER誘導体:638(M+),623,607,548,508,405,404,315,314,274,273(032)"		"033/032/"	"動物の白血球，肥満細胞，気管支，肺，消化管，脳などにその合成酵素が存在し， 刺激に応じて新規に生合成される．"		"・気管支収縮，気道粘液分泌，血管透過性亢進，血管収縮，腸管収縮など．・ＬＴＤ4受容体を介して生物作用を発現するものと考えられる．"			
"PR0010"	13.00	"5(S),6(S)-EPOXYICOSA-7(E),9(E),11(Z),14(Z)-TETRAENOIC ACID"	"LEUKOTRIENE A4"	"LTA4"	"OUB"	"C20H30O3"	20.00	30.00	3.00	0.00	0.00	0.00	318.00	"                   H                                        (REF:034)"	"                   �ｵ      COOH"	"     �ｷ＼�ｷ＼�ｷ＼／�ﾗ／＼／"	"     �ｵ        �ﾄ�ﾖO"	"     �ｵ       H"	"     �ｵ"	"     ＼�ｧ／＼／＼／"					"034/"			"[α]25/D=-21.9(C,0.32,CYCLOHEXANE)  (030)"			"SOL. IN CYCLOHEXANE,METHANOL(030) / STABILITIES:中性付近の水溶液中(37ﾟC)で 半減期約１分で分解して 5,12-DIHYDROXY-6,8,10,14-ICOSATETRAENOIC ACIDと 5,6-DIHYDROXY-7,9,11,14-ICOSATETRAENOIC ACIDになる．(036)"	"030/036/"	"METHYL ESTER: λmax=269(ε30,500),278(ε40,000),287(ε34,400)nm (IN MeOH)  (037)"			"METHYL ESTER: 332(M+),316,300,221,189,181,129,101(035)"		"037/035/"	"動物の白血球，肥満細胞，マクロファージなどでＬＴＢ4やＬＴＣ4の生合成の中間 体として合成される．"		"ロイコトリエンの生成過程における中間代謝産物であり，明かな生物活性は報告さ れていない．"			
"PR0011"	13.00	"7-[3-(3(S)-HYDROXY-1(E)-OCTENYL)-1(S),5(S),4,6-DIOXABICYCLO[3.1.1]HEPT-2-YL]-5(Z)-HEPTENOIC ACID"	"THROMBOXANE A2"	"TXA2"	"OUB"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"    ／�ﾊ�ﾄ＼�ｧ／＼／＼COOH                                (REF:038)"	"    �ﾓO｜"	"    ＼／�ﾖ�ｷ＼／＼／＼／"	"     O        �ﾂ"	"              OH"							"038/"						"STABILITIES: 中性付近の水溶液中(37ﾟC)で, 半減期約40秒で分解して TXB2と 12-HYDROXY-5,8,10-HEPTADECATRIENOIC ACIDになる．(039)"	"039/"							"動物の血小板，腎，肺などにその合成酵素が存在し，刺激に応じて新規に生合成さ れる．"		"・血小板凝集，血管収縮，気管支収縮． ・ＴＸＡ2受容体を介して生物作用を発現するものと考えられる．"			
"PR0012"	13.00	"7-[TETRAHYDRO-4(S),6-DIHYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-2H-PYRAN-3 (S)-YL]-5(Z)-HEPTENOIC ACID"	"THROMBOXANE B2"	"TXB2"	"OUB"	"C20H34O6"	20.00	34.00	6.00	0.00	0.00	0.00	370.00	"        OH                                       (REF:040)"	"        �ﾂ"	"      ／＼�ﾄ＼�ｧ／＼／＼COOH"	"     ｜  ｜"	"  HO�ﾎ＼／�ﾔ�ｷ＼／＼／＼／"	"       O        �ﾂ"	"                OH"					"040/"	"95-96 (041)"		"[α]25/D=57.4(C 0.26 ETHYL ACETATE) (041)"			"SOL. IN ETHYL ACETATE(043)"	"041/043/"		"FILM: ν3380,1705cm-1 (041)"	"CDCl3: δ5.86(m,1H,14-CH),5.72(m,1H,13-CH),5.46(m,2H,5,6-CH),5.35 AND5.23(m,1H,11CH),4.41(m,1H,12-CH),4.22(m,1H,15-CH),4.11(m,1H,9-CH), 2.35(t, 2H,2-CH2),0.89(m,3H,20-CH3)(042)"	"m/e 335,317(041)"		"041/042/"	"動物の血小板，腎，肺，などにＴＸＡ2の合成酵素が存在し，刺激に応じて新規に合成されたものが分解して，ＴＸＢ2となる．"		"ＴＸＡ2の分解産物で顕著な生物活性は報告されていない．"			
"PR0013"	13.00	"5(S),6(R),15(S)-TRIHYDROXYICOSA-7(E),9(E),11(Z),13(E)-TETRAENOIC ACID"	"LIPOXIN A4"	"LXA4"	"OUT"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"               OH H                                         (REF:044/046)"	"              �ﾒ�ﾄ      COOH"	"  �ｷ＼�ｷ＼�ｷ＼／＼／＼／"	" ｜         �ﾕ�ﾅ"	"  �ｸ       H    OH"	"  �ｶ�ｽ"	"  �ﾕ�ﾂ＼／＼／"	" H  OH"				"044/046/"						"SOL. IN DIETHYLETHER,METHANOL(045)"	"045/"	"CH3OH:λmax=287,301(ε50,000),316nm  (045/046)"		"250MHz, 5% CD3OD/D2O: δ0.8-0.9(brt,3H),1.2-1.8(m,14H),2.1-2.3(m,2H),3.4-  3.6(m,1H),3.95-4.05(t,J=6.8Hz,1H),4.1-4.2(q,J=7.1Hz,1H),5.6-5.85(seven linem,2H),5.9-6.1(m,2H), 6.2-6.45(m,2H),6.6-6.8(m,2H)(045)"	"TMS誘導体: 582(M+),492,482,379,289,203,173,171(044)"		"045/046/044/"	"動物の白血球で刺激に応じて新規に生合成される．"		"・気管支収縮  ・多形核白血球の活性化（走化作用，ﾘｿｿﾞｰﾑ酵素の遊離，ｽｰﾊﾟｰｵｷｼﾄﾞｱﾆｵﾝ産生）   ・NK細胞の細胞障害活性の抑制・ﾌﾟﾛﾃｲﾝｷﾅｰｾﾞCの活性化"			
"PR0014"	13.00	"5,14,15-TRIHYDROXYICOSA-6,8,10,12-TETRAENOIC ACID"	"LIPOXIN B4"	"LXB4"	"OUT"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"      HO  H      <isomer A>                       HO  H   (REF:047/048/050)"	"      �ﾒ�ﾄ      COOH                              �ﾒ�ﾄ      COOH"	"  ／�ｸ／＼／＼／              HO�ﾜ／�ｸ／�ｸ／�ｸ／�ｸ／＼／＼／"	"  �ｾ                            �ｶ"	"  �ｾ        HO  H               �ﾕ�ﾊ／＼／           <isomer B>"	"  �ｾ        �ﾒ�ﾄ               H  OH"	"  ＼�ｷ＼�ｷ＼／＼／＼／＼      isomer A:(5S,6E,8Z,10E,12E,14R,15S) FORM"	"          �ﾃ�ﾔ                isomer B:(5S,6E,8E,10E,12E,14R,15S) FORM"	"          HO H                isomer C:(5S,6E,8E,10E,12E,14S,15S) FORM"	"               上記３化合物の混合物（現在ではisomer AのみをLIPOXIN B4と呼び"	"               他の２つはLIPOXIN B4の異性体と考えるのが主流）"	"047/048/050/"			"METHYL ESTER:[α]20/D=19.2(C 1.16, CHCl3)  (049)"			"SOL. IN METHANOL (047)"	"049/047/"	"ISOMER A: λMeOH/max=288, 300(ε50,000), 315nm  (048)"	"ISOMER A, METHY ESTER, IN CHCl3: λ3610,3470,3030,3015,2960,2935,2860,1735,1605,1440,1230,1000,980cm-1(049)"	"ISOMER A: CDCl3,250MHz:δ6.68(m,2H),6.36(dd,J=14.8 AND 10.5Hz,1H),6.23(dd, J=14.1 AND10.7Hz,1H),6.0(m,2H),5.75(m,2H),4.17(m,2H),3.70(m,1H),3.65(s,3H),2.34(t,J=7.1Hz,2H),1.78-1.21(m,12H),0.86(t,J=6.4Hz,3H)(049)"	"ISOMER A:TRIMETHYLSILYLETHER METHYL ESTER: 582(M+),492,482,409,402,379,329,319,307,289,203,173(048)"		"048/049/"	"動物の白血球で刺激に応じて生合成される．"		"NK細胞の細胞障害作用の抑制．"			
"PR0015"	13.00	"5(Z),8(Z),11(Z),14(Z)-ICOSATETRAENOIC ACID"	"ARACHIDONIC ACID"	"AA"	"UT4"	"C20H32O2"	20.00	32.00	2.00	0.00	0.00	0.00	304.00	"                    COOH                                (REF:051)"	"  ／�ｦ＼／�ｦ＼／＼／"	"／"	"＼"	"  ＼�ｧ／＼�ｧ／＼／＼／"							"051/"	"-49.5 (052)"			"n/D=1.4824 (052)"			"052/"		"METHYL ESTER :ν3030,1735,965,700cm-1(053)"	"CHARTが記載 (054)"	"METHYL ESTER: 347(M+/+29),319(M+/+1),303,287,249,235,221(057)"		"053/054/057/"	"ほとんどの動物組織で，リン脂質にエステル結合した形で存在する． プロスタグランジン，トロンボキサン，ロイコトリエンなどの生理活性物質の前駆 体となる．"					
"PR0016"	13.00	"7-[2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-5-OXO-3-CYCLOPENTEN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN A2"	"PGA2"	"OUB"	"C20H30O4"	20.00	30.00	4.00	0.00	0.00	0.00	334.00	"                                                        (REF:089)"	"           O"	"           �ｾ�ﾄ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ"	"         �ｱ�ｼ�ｵ            COOH"	"         �ｸ�ｽ�ｵ              CH3"	"             �ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"                   �ﾂ"	"                   OH"				"089/"			"[α]20/D=+140ﾟ(C 1.15 CHCl3)   (059)"			"ETOH, CHCl3, MEOH, ET2O(006)"	"006/059/"	"EtOH: 217 nm (ε9900)(006)"	"NUJOL: 3400,1705,1580,1255,1115,1070,1015 cm-1(006)"	"1H-NMR(CDCl3):δ 7.57(dd,1H,10-CH),6.2(dd,1H,11-CH),5.6(m,2H,13,14-CH),5.4(m,2H,5,6-CH),4.12(1H,m,12-CH),3.23(m,1H),0.89(t,3H,20-CH3)(060)
13C-NMR(ME ESTER,CDCl3) 210.3,174.0,165.0,135.2,133.3,131.0,130.2,126.7,72.4,52.1,51.5,49.6,37.3,33.5,31.8,27.4,26"	"m/e 334(M+),316,190(006)"""	"(089)"	"006/060/061/089/"	"動物の精液など．PGE2の非酵素的分解により生成する．動物の血清中にPGE2をPGA2 に変換する酵素活性の存在が報告されている．"		"腫瘍細胞増殖抑制"			
"PR0017"	13.00	"7-[2-(3(S)-HYDROXY-1(E)-OCTENYL)-5-OXO-1-CYCLOPENTEN-1-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN B2"	"PGB2"	"OUB"	"C20H30O4"	20.00	30.00	4.00	0.00	0.00	0.00	334.00		"          O"	"          �ｾ�ｱ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ"	"        �ｱ�ｼ�ｾ            COOH"	"        �ｲ  �ｾ              CH3"	"          �ｼ�ｲ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"                  �ﾂ"	"                  OH"														"1H-NMR(ME ESTER):δ 6.9(d,J=16Hz,1H,13-CH),6.3(dd,J=5.5,16Hz,1H,14-CH),5.7-5.1(m,2H),4.5-4.1(m,1H,15-CH),3.65(S,3H,OCH3),3.15-2.85(m,2H,7-CH)(062)"	"ME ESTER; m/e 348(M+),317,249,247,245,217,215,133,119,109 (062)"		"062/"	"""動物の精液など．PGE2の非酵素的分解により生成する．動物の血清中にPGE2をPGA2,PGC2を経てPGB2に変換する酵素活性の存在が報告されている．"		"明かな生物活性は報告されていない．"			
"PR0018"	13.00	"7-[2-(3(S)-HYDROXY-1(E)-OCTENYL)-5-OXO-2-CYCLOPENTEN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN C2"	"PGC2"	"OUB"	"C20H30O4"	20.00	30.00	4.00	0.00	0.00	0.00	334.00		"          O                                        (063)"	"          �ｾ�ﾄ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ"	"        �ｱ�ｼ�ｵ            COOH"	"        �ｲ�ｧ�ｵ              CH3"	"            �ｲ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"                  �ﾂ"	"                  OH"				"063/"						"MEOH,CHCl3(064)"	"064/"	"λmax MEOH 234 nm (ε 17000) (064)"	"CHCl3,ν1750,1715 cm-1(064)"	"ME ESTER;δ 6.3(d,J=16Hz,1H,13-CH),6.1-5.95(m,2H,11-CH),5,7(dd,J=6,16Hz,1H,14-CH), 5.7-5.1(m,2H,5,6-CH),4.4-4.0(m,1H,15-CH),3.69(S,3H,OCH3),3.3- 3.0(m,1H,8-CH),3.0-2.8(m,2H,10-CH) (062)"	"ME ESTER; m/e 348(M+),330,249,245,217,215,190,133,119,109(062)"		"062/"	"動物の血清中にPGA2をPGC2に変換する酵素活性の存在が報告されている．"		"明かな生物活性は報告されていない．"			
"PR0019"	13.00	"7-[2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-3-OXO-4-CYCLOPENTEN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"PROSTAGLANDIN J2"	"PGJ2"	"OUB"	"C20H30O4"	20.00	30.00	4.00	0.00	0.00	0.00	334.00		"                                                 (065)"	"            �ﾄ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ"	"        �ｴ�ｼ�ｵ            COOH"	"        �ｲ�ｽ�ｵ              CH3"	"          �ｾ�ﾖ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"          O       �ﾂ"	"                  OH"				"065/"						"CHCl3,ETOH(066)"	"066/"	"λmax ETOH 305(ε1200),216(ε9900)nm(066)"	"ν3400,3200,2660,1710,1085,970 cm-1(066)"	"IH-NMR(CDCl3):δ7.75-7.55(m,1H,9-CH),6.30-6.10(m,1H,10-CH),5.90(brs,2H,OH),5.75-5.35(m,4H),4.30-3.95(m,1H,15-CH)(066)"	"TMS ETHER; M+ 478.2934(066)"		"066/"	"PGD2の非酵素的分解で生成する．"		"腫瘍細胞増殖抑制"			
"PR0020"	13.00	"7-[2(E)-(3(S)-HYDROXYOCTYLIDENE)-3-OXO-4-CYCLOPENTEN-1(R)-YL]-5(Z)-HEPTENOIC ACID"		"Δ12-PGJ2"	"OUB"	"C20H30O4"	20.00	30.00	4.00	0.00	0.00	0.00	334.00		"                                                 (067)"	"            �ﾄ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ"	"        �ｴ�ｼ�ｵ            COOH"	"        �ｲ�ｽ�ｵ              CH3"	"          �ｾ�ｸ�ｱ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"          O       �ﾂ"	"                  OH"				"067/"						"ETOH,CHCl3,ETHYL ACETATE (068)"	"068/"	"λmax ETOH 244(ε6100)nm (068)"	"λmax:2930,1700,1640,1580,1232,1028 cm-1 (068)"	"1H-NMR(CDCl3):δ7.5(dd,1H,9-CH),6.56(t,1H,13-CH),6.35(dd,1H,10-CH),5.48(m, 2H,5,6-CH),3.88(m,1H,15-CH),3.44(m,1H,8-CH)(068)"	"m/e 334(M+),316,245,236 (068)"		"068/"	"動物の血清，尿など．PGD2からPGJ2を経由して非酵素的に生成する．"		"腫瘍細胞増殖抑制"			
"PR0021"	13.00	"7-[3(R),5(S)-DIHYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)CYCLOPENTAN-1(R)-YL]-6-OXOHEPTANOIC ACID"	"6-KETOPROSTAGLANDIN F1α"	"6-KETO-PGF1α"	"OUB"	"C20H36O6"	20.00	36.00	6.00	0.00	0.00	0.00	372.00		"      HO                  COOH                         (069)"	"        �ﾅ  �ﾄ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"        �ｱ�ｼ�ｵ  �ｾ"	"        �ｲ�ｽ�ｵ  O            CH3"	"        �ﾄ  �ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"      HO          �ﾂ"	"                  OH"				"069/"			"[α]21/D -9.6ﾟ C1.04  MEOH(070)"			"MEOH,ACETONE,ETHYL ACETATE(070)"	"070/"		"NEAT:ν3400,1715,1245,1045,975,915,875,845,800,730 cm-1 (070)"	"1H-NMR(ACETONE-D6):δ6.1-5.4(bs,4H),5.5-5.2(m, 2H),4.7-3.5(m,3H),2.5-1.1(m,22H),0.86(t,3H)"	"METHYL ESTER ;366(M+-18),348,335,330,323,319,279,265,223,196,195,164,143,  121,111,99,95,71 (070) 
DIRECT EXPOSURE AMMONIA CI POSITIVE:370,353,244,163,153,136, NEGATIVE:368,351,334,316,225,219,166, 135,127       (071)"""		"070/071/"	"動物の血管にPGI2の合成酵素が存在し，刺激に応じて新規に合成されたものが，非酵素的に分解して6ｰｹﾄｰPGF1αとなる．"		"明かな生物活性は報告されていない．"			
"PR0022"	13.00	"7-[3(R)-HYDROXY-2(R)-(3-OXO-1(E)-OCTENYL)-5-OXOCYCLOPENTAN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"15-KETOPROSTAGLANDIN E2"	"15-KETO-PGE2"	"OUB"	"C20H30O5"	20.00	30.00	5.00	0.00	0.00	0.00	350.00		"          O                                           (090)"	"          �ｾ�ﾄ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ"	"        �ｱ�ｼ�ｵ            COOH"	"        �ｲ�ｽ�ｵ              CH3"	"        �ﾄ  �ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"      HO          �ｾ"	"                  O"				"090/"								"METHYL ESTER  λ MEOH/max 227nm (ε〜9000)  (072)"			"DIMETHOXIME TMS ETHER METHYL ESTER ; m/z 494(M+),479,463,404,373,321,180(072)"		"072/"	"動物の肺，腎，胎盤，脾などでPGE2から生成される．"		"PGE2が代謝され，その生物活性を失う最初のｽﾃｯﾌﾟの反応産物であり，明かな生物  活性はない．"			
"PR0023"	13.00	"7-[3(R),5(S)-DIHYDROXY-2(R)-(3-OXO-1(E)-OCTENYL)CYCLOPENTAN-1(R)-YL]-5(Z)-HEPTENOIC ACID"	"15-KETOPROSTAGLANDIN F2α"	"15-KETO-PGF2α"	"OUB"	"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00		"       OH"	"        �ﾅ  �ﾄ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ"	"        �ｱ�ｼ�ｵ            COOH"	"        �ｲ�ｽ�ｵ              CH3"	"        �ﾄ  �ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"      HO          �ｾ"	"                  O"																		"動物の肺，腎，胎盤，脾などでPGF2αから生成される．"		"PGF2αが代謝されてその生物活性を失う最初のｽﾃｯﾌﾟの反応産物であり，明かな生物活性はない．"			
"PR0024"	13.00	"5-[TETRAHYDRO-4(S),6-DIHYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-2H-PYRAN-3(S)-YL]-3(Z)-PENTENOIC ACID"	"2,3-DINORTHROMBOXANE B2"	"2,3-DINOR-TXB2"	"OUB"	"C18H30O6"	18.00	30.00	6.00	0.00	0.00	0.00	342.00	"          OH"	"          �ﾂ                                          (073)"	"        �ｱ�ｲ�ﾄ�ｲ�ｧ�ｱ�ｲ"	"        �ｵ�ｶ          COOH  CH3"	"    HO�ﾎ�ｲ�ｱ�ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"         O        �ﾂ"	"                  OH"					"073/"						"ETHYL ACETATE,ETHYL ETHER,DICHLOROMETHANE(074)"	"074/"			"METHYL ESTER 1H-NMR(CDCl3):δ5.77-5.0(m,6H),4.50-3.96(m,5H),3.71(s,3H,OCH3),3.20-3.00(m,2H)(074)"	"METHYL ESTER TRIS-TMS ETHER m/e 557,482,467,411,338,301,295,267,228,225, 217 (073)"		"073/074/"	"動物の血清，尿など．"		"TXB2の代謝産物で，明かな生物活性はない．"			
"PR0025"	13.00	"7-[TETRAHYDRO-4(S)-HYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-6-OXO-2H-PYRAN-3(S)-YL]-5(Z)-HEPTENOIC ACID"	"11-DEHYDROTHROMBOXANE B2"	"11-DEHYDRO-TXB2"	"OUB"	"C20H32O6"	20.00	32.00	6.00	0.00	0.00	0.00	368.00	"          OH"	"          �ﾂ                                          (074/075)"	"        �ｱ�ｲ�ﾄ�ｲ�ｧ�ｱ�ｲ／＼COOH"	"        �ｵ�ｶ                CH3"	"      �ｴ�ｲ�ｱ�ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"     O    O       �ﾂ"	"                  OH"					"074/075/"						"METHANOL,ETHYL ACETATE (075)"	"075/"		"METHYL ESTER; CHCl3 ν1730 cm-1(074)"	"METHYL ESTER CDCl3:δ5.86-5.78(m,2H),5.56-5.32(m,2H),5.13-4.72(m,1H), 5.23-4.05(m,2H),3.67(S,3H,OCH3)(074)"	"METHYL ESTER BIS-TMS ETHER; m/e 526(M+),511,455,370,295 (074)"""		"074/075/"	"動物の血清，尿など．"		"TXB2の代謝産物で，明かな生物活性はない．"			
"PR0026"	13.00	"5-[3(R),5(S)-DIHYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)CYCLOPENTAN-1(R)-YL]-4-OXOPENTANOIC ACID"	"2,3-DINOR-6-KETOPROSTAGLANDIN F1α"	"2,3-DINOR-6-KETO-PGF1α"	"OUB"	"C18H32O6"	18.00	32.00	6.00	0.00	0.00	0.00	344.00		"       OH             COOH                               (076)"	"        �ﾅ  �ﾄ�ｲ�ｱ�ｲ�ｱ"	"        �ｱ�ｼ�ｵ  �ｾ"	"        �ｲ�ｽ�ｵ  O           CH3"	"        �ﾄ  �ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"      HO          �ﾂ"	"                  OH"				"076/"						"METHANOL (076)"	"076/"				"METHOXIME TRI-TMS ETHER METHYL ESTER; m/e 601(M+),586,570,530,511,496,480, 440,421,390,350,300,294,263,217,205,191,173  (076)"""		"076/"	"動物の血清，尿など．"		"6ｰｹﾄｰPGF1αの代謝産物で，明かな生物活性はない．"			
"PR0027"	13.00	"8-[2(R)-(2-CARBOXYETHYL)-5(R)-HYDROXY-3-OXO-CYCLOPENTAN-1(R)-YL]-6-OXO-OCTANOIC ACID"	"PROSTAGLANDIN E-MAJOR URINARY METABOLITE"	"PGE-MUM"	"OUB"	"C16H24O7"	16.00	24.00	7.00	0.00	0.00	0.00	328.00		"          O       COOH                               (077)"	"          �ｾ�ﾄ�ｲ�ｱ"	"        �ｱ�ｼ�ｵ"	"        �ｲ�ｽ�ｵ              COOH"	"        �ﾄ  �ﾔ�ｱ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"      HO          �ｾ"	"                  O"				"077/"						"ETHYL ACETATE(077)"	"077/"				"DIMETHYL ESTER DI-O-METHYLOXIME TMS ETHER DERIVATIVE; 486,455,369,365,355, 286,279,268,265,196,115 077)"		"077/"	"動物の血清，尿など．"		"PGE2の最終代謝産物で，明かな生物活性はない．"			
"PR0028"	13.00	"8-[2(R)-(2-CARBOXYETHYL)-3(S),5(R)-DIHYDROXYCUCLOPENTAN-1(R)-YL]-6-OXO-OCTANOIC ACID"	"PROSTAGLANDIN Fα-MAJOR URINARY METABOLITE"	"PGFα-MUM"	"OUB"	"C16H26O7"	16.00	26.00	7.00	0.00	0.00	0.00	330.00		"      HO          COOH                               (078)"	"        �ﾅ  �ﾄ�ｲ�ｱ"	"        �ｱ�ｼ�ｵ"	"        �ｲ�ｽ�ｵ              COOH"	"        �ﾄ  �ﾔ�ｱ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"      HO          �ｾ"	"                  O"				"078/"											"DIMETHYL ESTER DI-TMS ETHER; m/e 502(M+),487,412,397,325,322,291,254,241,  228,217,191,179,143(078)"		"078/"	"動物の血清，尿など．"		"PGF2αの最終代謝産物で明かな生物活性はない．"			
"PR0029"	13.00	"5(S)-HYDROXY-6(R)-S-CYSTEINYLICOSA-7(E),9(E),11(Z),14(Z)-TETRAENOIC ACID"	"LEUKOTRIENE E4"	"LTE4"	"OUB"	"C23H37O5NS"	23.00	37.00	5.00	1.00	0.00	1.00	439.00	"                      OH"	"                      �ﾁ      COOH                              (029)"	"        �ｴ�ｲ�ｷ�ｲ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"        �ｵ          �ﾂ     COOH"	"        �ｵ          S�ｭ�ｲ�ｱ"	"        �ｵ               �ﾀ"	"        �ｵ           CH3 NH2"	"        �ｲ�ｧ�ｱ�ｲ�ｱ�ｲ�ｱ"				"029/"			"DIMETHYL ESTER [α]20/D +35.2ﾟ (079)"			"METHANOL (079/080)"	"079/080/"	"270(ε40000),280(49400),291nm(40000)(080)"		"DIMETHYL ESTER:1H-NMR(CDCl3):δ6.33(dd,J=14.5,10Hz,1H,10CH),6.0(t,J=10Hz,  1H,11-CH)5.62(dd,J=14.4,9.6Hz,1H,7-CH),5.3(m,J=10,9Hz,1H,14-CH),3.71 AND 3.62(2S,6H,OCH3)3.65(m,1H,5-CH),3.4(m,1H,6-CH),2.95(t,J=9Hz,2H,13-CH),2.02(m,2H,16-CH),0.86(t,J=6Hz,3H,20-"			"079/080/"	"動物の白血球，ﾏｸﾛﾌｧｰｼﾞ，肥満細胞，肺，腸管などで，刺激に応じて新規に合成さ たLTC4が代謝されてLTE4となる．"		"気管支収縮，気道粘液の分泌，血管透過性亢進，腸管収縮，血管収縮"			
"PR0030"	13.00	"5(S)-HYDROXY-6(R)-S-GLUTAMYLCYSTEINYLICOSA-7(E),9(E),11(Z),14(Z)-TETRAENOIC ACID"	"LEUKOTRIENE F4"	"LTF4"	"OUB"	"C28H44O8N2"	28.00	44.00	8.00	2.00	0.00	0.00	536.00	"                      OH"	"                      �ﾁ      COOH                              (081)"	"        �ｴ�ｲ�ｷ�ｲ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"        �ｵ          �ﾂ     COOH"	"        �ｵ          S�ｭ�ｲ�ｱ"	"        �ｵ               �ﾀ          COOH"	"        �ｵ           CH3 NHCO�ｮ�ｱ�ｲ�ｱ"	"        �ｲ�ｧ�ｱ�ｲ�ｱ�ｲ�ｱ             �ﾀ"	"                                   NH2"			"081/"								"λ270sh,280(ε40000),290sh nm (082)"	"N-TRIFLUOROACETYL METHYL ESTER  ν3300,1720,1650,1200,985cm-1 (083)"	"N-TRIFLUOROACETYL METHYL ESTER 1H-NMR(CDCl3): δ 6.9-5.2(m,8H),5.0-4.5(m,  2H),3.8-3.6(m,1H,5-CH),3.79(s,3H,OCH3),3.76(s,3H,OCH3),3.67(s,3H,OCH3), 3.6-3.3(m,1H,6-CH),3.1-2.7(m,4H),0.9(t,J=7Hz,3H,20-CH3)"""	"N-TRIFLUOROACETYL METHYL ESTER 701(M+),688,675,674,662,657,649,648,578,550,465 (083)"		"082/083/"	"動物の生体内で実際に生合成されているかどうか不明である．"		"不明"			
"PR0031"	13.00	"5(S)-HYDROXY-6(R)-S-(N-ACETYLCYSTEINYL)ICOSA-7(E),9(E),11(Z),14(Z)-TETRAENOIC ACID"	"N-ACETYL-LEUKOTRIENE E4"	"N-ACETYL-LTE4"	"OUB"	"C25H39O6NS"	25.00	39.00	6.00	1.00	0.00	1.00	481.00	"                      OH"	"                      �ﾁ      COOH                              (084)"	"        �ｴ�ｲ�ｷ�ｲ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"        �ｵ          �ﾂ     COOH"	"        �ｵ          S�ｭ�ｲ�ｱ"	"        �ｵ               �ﾀ"	"        �ｵ           CH3 NHCOCH3"	"        �ｲ�ｧ�ｱ�ｲ�ｱ�ｲ�ｱ"				"084/"								"λ280nm(270sh,290sh)(084)"					"084/"	"動物の胆汁など．LTC4やLTD4の代謝産物．"		"顕著な生物活性は報告されていない．"			
"PR0032"	13.00	"5(Z),8(Z),11(Z)-ICOSATRIENOIC ACID"			"UT3"	"C20H34O2"	20.00	34.00	2.00	0.00	0.00	0.00	306.00			"                          COOH"	"        �ｱ�ｦ�ｲ�ｱ�ｦ�ｲ�ｱ�ｲ�ｱ"	"      �ｱ"	"      �ｲ"	"        �ｲ�ｧ�ｱ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ�ｲ"	"                            CH3"										"CARBON DISULFIDE,HEPTANE,METHANOL (085)"	"085/"			"METHYL ESTER: 1H-NMR (CDCl3) δ5.3(t,6H),3.7(s,3H,OCH3),2.8(t,4H),2.25(t,  2H),2.0(d,4H),1.7(m,4H),1.3(bm,10H),0.9(t,3H)(086)"	"METHYL ESTER m/e 320(086)"		"086/"	"動物の多くの組織でﾘﾝ脂質にｴｽﾃﾙ結合した形で存在する．"		"3群のﾛｲｺﾄﾘｴﾝの前駆体となる．"			
"PR0033"	13.00	"8(Z),11(Z),14(Z)-ICOSATRIENOIC ACID"	"BISHOMO-γｰLINOLENIC ACID"	"DHLA"	"UT3"	"C20H34O2"	20.00	34.00	2.00	0.00	0.00	0.00	306.00				"        �ｱ�ｦ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ�ｲ"	"      �ｱ                  COOH"	"      �ｲ                    CH3"	"        �ｲ�ｧ�ｱ�ｲ�ｧ�ｱ�ｲ�ｱ�ｲ�ｱ"											"CARBON DISULFIDE,HEPTANE,METHANOL(085)"	"085/"				"上にCHART記載 (087)"		"085/087/"	"動物の多くの組織でﾘﾝ脂質にｴｽﾃﾙ結合した形で存在する．"		"1群のﾌﾟﾛｽﾀｸﾞﾗﾝｼﾞﾝとﾄﾛﾝﾎﾞｷｻﾝの前駆体となる．"			
"PR0034"	13.00	"4(Z),7(Z),10(Z),13(Z),16(Z),19(Z)-DOCOSAHEXAENOIC ACID"	"DOCOSAHEXAENOIC ACID"	"DHA"	"UT6"	"C22H32O2"	22.00	32.00	2.00	0.00	0.00	0.00	328.00				"        �ｱ�ｦ�ｲ�ｱ�ｦ�ｲ�ｱ�ｲ"	"      �ｱ                COOH"	"      �ｲ"	"        �ｲ�ｧ�ｱ�ｲ�ｧ�ｱ�ｲ�ｧ�ｱ�ｲ�ｧ�ｱ�ｲ"	"                                  CH3"					"-44.5〜-44.1 (085)"				"n26/D=1.5017 (085)"	"BENZEN,CHLOROFORM,METHANOL,PETROLEUM ETHER(085)"	"085/"				"上にCHART記載 (088)"		"085/088/"	"動物の多くの組織でﾘﾝ脂質にｴｽﾃﾙ結合した形で存在する．"		"不明"			
"PR0035"	13.00	"7-[3(R)-HYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-5-OXOCYCLOPENTAN-1(R)-YL]- 6-OXOHEPTANOIC ACID"	"6-KETO-PROSTAGLANDIN E1"	"6-KETO-PGE1"	"OUB"	"C20H32O6"	20.00	32.00	6.00	0.00	0.00	0.00	368.00		"          O               COOH                               (087)"	"          �ｾ�ﾄ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"        �ｱ�ｼ�ｵ  �ｾ"	"        �ｲ�ｽ�ｵ  O           CH3"	"        �ﾄ  �ﾔ�ｷ�ｲ�ｱ�ｲ�ｱ�ｲ�ｱ"	"      HO          �ｾ"	"                  O"				"091/"	"65ﾟC (070)"		"[α]20/D -50ﾟ C1.55 METHANOL (070)"			"METHANOL,CHLOROFORM(070)"	"070/"		"(KBr): ν3400,1740,1720,1710,1245,1160,1075,970 cm-1 (070)"	"1H-NMR(CD3OD):δ5.58(m,2H,13,14-CH),4.09(m,1H,11-CH),4.02(m,1H,15-CH),2.7  (2H,7-CH),2.69(IH,10β-CH),2.45-2.47(m,3H,5,8,12-CH),2.29(1H,10α-CH),     2.28(2H,2-CH),1.58〜1.32(12H),0.91(t,3H,20-CH3)   (092)
METHYL ESTER:13C-NMR(CDCl3);216.6,208.4,173.8,13"	"DIRECT EXPOSURE AMMONIA CI: POSITIVE:386(M+ +18),368(M+),351,350,244,136NEGATIVE:368(M+),350,338,332(071)"		"070/071/088/"	"動物の肝臓などで，PGI2あるいは6ｰｹﾄｰPGF1αから生合成する酵素が報告されている．"		"血管拡張，血小板凝集抑制"			
"PR0036"	13.00	"8-HYDROXY-11,12(S,S)-EPOXYEICOSA-5,14(Z,Z),9(E)-TRIENOIC ACID"	"HEPOXILIN A3"	"HxA3"		"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"             HO                                               (REF:021)"	"               �ﾜ              COOH"	"           ／�ｹ／＼／�ｦ＼／＼／"	"        O�ﾄ�ｵ"	"         �ﾅ�ｵ"	"         ／"	"         ＼�ｧ／＼／＼／"					"021/"						"ETHYL ETHER (023)"	"023/"				"METHYL ESTER TMS ETHER: M/E 422[M+],407,391,332,311,282,269(BASE PEAK)(022)"		"022/"	"ラットの脳や膵の潅流実験やホモジネートとアラキドン酸との反応で生成する。 12-HPETEから非酸素的に生成することがわかっているが、12-HPETEを特異的にHEPOXILINに変換する酵素が存在するかどうかは不明である(001/002)。"	"001/002/"	"ラット海馬のノルエピネフリン放出を抑制(003)。ラット膵のインスリン分泌を促進(004)。"	"003/004/"		
"PR0037"	13.00	"10-HYDROXY-11(R),12(S)-EPOXYEICOSA-5,8,14(Z,Z,Z)-TRIENOIC ACID"	"HEPOXILIN B3"			"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"                                                              (REF:024)"	"                             COOH"	"       HO�ﾜ／�ｦ＼／�ｦ＼／＼／"	"           ＼"	"      O    ／"	"       �ﾅ／"	"         ＼／�ｦ＼／＼／＼"					"024/"			"ACETATE METHYL ESTER [α]23/D=-10.9(C=0.11,CHCl3) (025)"			"ETHYL ETHER (023)"	"025/023/"		"ACETATE METHYL ESTER : CHCl3,ν2956,1743,1550,1372,1234,1033,999cm-1(025)"	"1H-NMR(C6D6)ACETATE METHYL ESTER:(025)δ 5.67(dd,J=9.2,6.4Hz,1H,10-CH),5.52,5.46,5.42,5.35,5.32,3.36(s,3H,OCH3),2.95(m,2H,7-CH),2.92(m,1H,11-CH),2.86(ddd,J=7.4,7.4,2.1Hz,1H,12-CH),2.30(ddd,J=14.8,7.4,7.4Hz,1H,13-CH),2.18(ddd,J=14.8,7.4,7.4Hz,1H,13-CH),2."	"METHYL ESTER TRIS-TMS ETHER: M/E 311,282,269(BASE PEAK)(007)"		"025/007/"	"血小板で生成(005)。"	"005/"				
"PR0038"	13.00	"8,11(R),12(S)-TRIHYDROXYEICOSA-(5Z,9E,14Z)-TRIENOIC ACID"	"TRIOXILIN A3"	"TrXA3"		"C20H34O5"	20.00	34.00	5.00	0.00	0.00	0.00	354.00	"                                                              (REF:021)"	"                           COOH"	"       HO�ﾜ／＼／�ｦ＼／＼／"	"           ＼"	"           �ｴ"	"           ＼"	"           ／�ﾖOH"	"         �ﾄ＼／�ｦ＼／＼／＼"	"       HO"			"021/"											"METHYL ESTER TRIS-TMS ETHER:M/E 444,384,371,353,281,243,213(BASE PEAK)(007)"		"007/"	"HEPOXILIN A3からラット肝のエポキシド水解酵素の作用で生成(006)。"	"006/"				
"PR0039"	13.00	"10,11(S),12(R)-TRIHYDROXYEICOSA-5,8,14(Z,Z,Z)-TRIENOIC ACID"	"TRIOXILIN B3"	"TrXB3"		"C20H34O5"	20.00	34.00	5.00	0.00	0.00	0.00	354.00	"                                                              (REF:024)"	"                             COOH"	"           ／�ｦ＼／�ｦ＼／＼／"	"     HO�ﾜ／"	"         ＼"	"           ＼  ／＼�ｧ／＼／＼／"	"           �ﾃ�ｼ�ﾀ"	"           HO  OH"				"024/"											"METHYL ESTER TRIS-TMS ETHER: M/E 342,315,269,225,213,129(BASE PEAK)(007)"		"007/"	"ラット肺可溶性画分が HEPOXILIN B3 に働いて生成(007)。"	"007/"				
"PR0040"	13.00	"5(S)-HYDROPEROXY-6,8,11,14-(E,Z,Z,Z)-EICOSATETRAENOIC ACID"		"5(S)-HPETE"		"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"                           OOH                                 (REF:026)"	"                           �ﾑ      COOH"	"           ／�ｦ＼／�ｦ＼�ｴ�ｼ＼／＼／"	"         ／"	"         ＼"	"           ＼�ｧ／＼／＼／"						"026/"						"ETHYL ETHER (027),ETHYL ACETATE (028)"	"027/028/"							"アラキドン酸 5-リポキシゲナーゼとアラキドン酸を反応させる時に生成する(008)"	"008/"	"ロイコトリエン生合成の中間体であることに生理的意義があって、生物活性に生理 的意味はないと思われる。"			
"PR0041"	13.00	"5(S)-HYDROXY-6,8,11,14-(E,Z,Z,Z)-EICOSATETRAENOIC ACID"		"5(S)-HETE"		"C20H32O3"	20.00	32.00	3.00	0.00	0.00	0.00	320.00	"                           OH                                 (REF:026)"	"                           �ﾑ      COOH"	"           ／�ｦ＼／�ｦ＼�ｴ�ｼ＼／＼／"	"         ／"	"         ＼"	"           ＼�ｧ／＼／＼／"						"026/"			"METHYL ESTER [α]23/D=+14.0ﾟ(C=2.0,BENZENE) (029)"			"ETHYL ETHER (009)"	"029/009/"	"METHYL ESTER  METHANOL : 235nm(ε=30,500)(009)"			"METHYL ESTER ETHER: M/E 406[M+],391,375,316,305,255,216,215,203,190,155,150,143,136,105,80,79 (009)"		"009/"	"アラキドン酸 5-リポキシゲナーゼがアラキドン酸と反応させる時に生成する 5-HPETEが、そのヒドロペルオキシド部分が酵素的あるいは非酵素的に還元されると生じる(009)。"	"009/"				
"PR0042"	13.00	"12(S)-HYDROPEROXY-5,8,10,14-(Z,Z,E,Z)-EICOSATETRAENOIC ACID"		"12(S)-HPETE"		"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"                                                              (REF:030)"	"                             COOH"	"           ／�ｦ＼／�ｦ＼／＼／"	"    HOO    �ｾ"	"       �ﾅ／"	"         �ｵ"	"         ＼�ｧ／＼／＼／"					"030/"						"ETHYL ETHER (027/030),ETHYL ACETATE (028)"	"027/030/028/"							"アラキドン酸 12-リポキシゲナーゼとアラキドン酸とを反応させる時に生成する   (010)。"	"010/"	"断片的な報告はあるが、多くの動物種と組織を通じて一般的な生理的役割は不明で ある。ラット松果体のメラトニン生成を促進(011)。アメフラシ神経伝達の第二メッセンジャー(016)。"	"011/016/"		
"PR0043"	13.00	"12(S)-HYDROPEROXY-5,8,10,14-(Z,E,Z,Z)-EICOSATETRAENOIC ACID"		"12(S)-HETE"		"C20H32O3"	20.00	32.00	3.00	0.00	0.00	0.00	320.00	"                                                              (REF:030)"	"                             COOH"	"           ／�ｦ＼／�ｦ＼／＼／"	"     HO    �ｾ"	"       �ﾅ／"	"         �ｵ"	"         ＼�ｧ／＼／＼／"					"030/"			"METHYL ESTER [α]25/D=+1.50ﾟ(C=0.2,CHCl3)(031),  [α]22/D=+13ﾟ(C=1.5,ACETONE)(032)"			"ETHYL ETHER , ACETONE , BENZENE (032)"	"031/032/"	"METHYL ESTER  METHANOL : 234nm(033)"	"NEAT:ν3480b,1710,1460,1400cm-1(032)"	"1H-NMR(250MHz,ACETONE-D6)(032)δ 0.87(t,J=6.3Hz,3H,20-CH),1.66 AND 2.14(m, 2H,4-AND 16-CH),2.22(m,2H,13-CH),2.27(t,J=7.4Hz,2H,2-CH),2.94(t,J=6.1Hz,2H,7-CH),4.16(q,J=6.3Hz,1H,12-CH),5.29(m,5H,5,6,8,14,15-CH),5.72(dd,J=15.3,6.2 Hz,1H,11-CH),5.97(t,J=11.0Hz"	"METHYL ESTER: M/E 316,303,223,191,141,107(BASE PEAK) (033)"		"033/032/"	"アラキドン酸 12-リポキシゲナーゼとアラキドン酸とが反応して生成する12-HPETE が、そのヒドロペルオキシド部分が酵素的あるいは非酵素的に還元されると生じる (010)。"	"010/"	"以下のように断片的な報告が種々あるが、多くの動物種と組織を通じて一般的な生 理的役割は不明である。ラット視床下部のLHRH分泌を亢進(012)。ヒト好酸球と好中球の走化性を亢進(013)。ラット大動脈平滑筋細胞の移動を亢進(014)。 腫瘍細胞IRGPIIb/IIIa受容体の発現あるいは"	"012/013/014/015/"		
"PR0044"	13.00	"15(S)-HYDROPEROXY-5,8,11,13-(Z,Z,Z,E)-EICOSATETRAENOIC ACID"		"15(S)-HPETE"		"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"                                                              (REF:034)"	"                             COOH"	"           ／�ｦ＼／�ｦ＼／＼／"	"         ／"	"         ＼"	"           ＼�ｧ／�ｸ�ｽ�ｽ／＼／＼／"	"                       �ﾂ"	"                       OOH"				"034/"						"ETHYL ETHER (027), ETHYL ACETATE(028), ETHANOL(034), METHANOL(035)"	"027/028/034/035/"			"1H-NMR(360MHz)METHYL ESTER:(035)δ 6.61(dd,J=11,15.5Hz,1H,13-CH),6.03(dd,J=10.5,11Hz,1H,12-CH),5.61(J=7.5Hz,1H,14-CH),5.46(dd,J=7.5,10.5Hz,1H,11-CH),5.39(m,4H,5,6,8,9-CH),4.39(m,1H,15-CH),3.67(s,3H,-OCH3),2.98(2H,10-CH),2.81(2H,7-CH),2.33(2H,2-CH),2.11"			"035/"	"ダイズ (017) あるいは網状赤血球 (018) のアラキドン酸 15-リポキシゲナーゼと アラキドン酸とを反応させる時に生成する。"	"017/018/"	"アラキドン酸 15-リポキシナーゼの生理的意義は不明なことが多いが、網状赤血球 のミトコンドリア膜リン脂質のエステル型アラキドン酸が、この酵素の作用を受け て過酸化され、赤血球への分化に際してミトコンドリア膜の破壊に寄与すると考えられている(019)。"	"019/020/"		
"PR0045"	13.00	"15(S)-HYDROPEROXY-5,8,11,13-(Z,Z,Z,E)-EICOSATETRAENOIC ACID"		"15(S)-HETE"		"C20H32O3"	20.00	32.00	3.00	0.00	0.00	0.00	320.00	"                                                              (REF:034)"	"                             COOH"	"           ／�ｦ＼／�ｦ＼／＼／"	"         ／"	"         ＼"	"           ＼�ｧ／�ｸ�ｽ�ｽ／＼／＼／"	"                       �ﾂ"	"                       OH"				"034/"						"ETHYL ETHER (034)"	"034/"	"METHYL ESTER : ISOOCTANE: 236nm(ε27200) (034)"		"1H-NMR(90MHz)METHYL ESTER:(034)δ 6.56(dd,J=11,14.5Hz,1H,13-CH),6.02(dd,J=11,11Hz,1H,12-CH),5.7(dd,J=6.8,14.5Hz,1H,14-CH),5.51(dd,J=6,11Hz,1H,11-CH),4.16(dd,J=6.8,6.8Hz,1H,15-CH),3.69(s,3H,-OCH3),2.98(2H,10-CH),2.84(2H,7-CH),2.35(2H,2-CH),2.08(2H,4-CH"	"METHYL ESTER TMS ETHER: M/E 406[M+],391,335,316,305,225,173 (034)"		"034/"	"アラキドン酸 15-リポキシゲナーゼとアラキドン酸とが反応して生成する 15-HPETEが、そのヒドロペルオキシ部分が酵素的あるいは非酵素的に還元されると生じる   (017)。"	"017/"				
"PR0046"	13.00	"[S-(Z,E,E)]-HYDROXY-5,8,10-HEPTADECATRIENOIC ACID"		"HHT"		"C18H30O3"	18.00	30.00	3.00	0.00	0.00	0.00	294.00	"                                                          (REF:127)"	"              COOH"	"    �ｴ＼／＼／"	"    �ｵ"	"    ＼"	"      �ｾ              CH3"	"      ＼�ｷ＼／＼／＼／"	"            �ﾂ"	"            OH"						"METHYL ESTER : [α]25/D = +7.5ﾟ(C=0.2,CHCl3) (146)"			"ETHYL ETHER (126)"	"146/126/"	"METHYL ESTER : ETHANOL 232nm(ε= 33,400), METHANOL 240nm (126/146)"		"METHYL ESTER : 'H-NMR(CDCl3)δ6.17(dd,J=15.11,10.36Hz,1H,10-CH), 6.04(dd,J=15,05,10.52Hz,1H, 9-CH), 5.66(dt, J=15.16, 6.48Hz, 1H), 5.60(dd, J=17.17, 7.04Hz, 1H, 11-CH), 5.42(m, 2H, 5-CH, 6-CH), 4.1(m, 1H, 12-CH), 3.66(s, 3H, COOCH3), 2.81(m, 2H, 7"	"METHYL ESTER TMS ETHER : M/E 366(M+), 335, 295, 276, 225, 173, (128)
METHYL ESTER : M+ 294, 224 (146)"		"126/146/128/"	"PGG2 やPGH2 のようなアラキドン酸から作られるPG edoperoxideが,TXA2 synthase と反応する時に，endoperoxide部分が開裂して，TXA2と同時に，ほぼ等量の炭素   １７個の 12−ヒドロキシトリエン酸を生成する。PG edoperoxideの非酸素的分解産物の１つでもあり、特に FeCl2"		"白血球の遊走・運動を亢進する(129)"	"129/"		
"PR0047"	13.00	"[R-(Z,Z,E,Z)]-12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID"		"12(R)-HETE"		"C20H32O3"	20.00	32.00	3.00	0.00	0.00	0.00	320.00	"                                                          (REF:130)"	"                          COOH"	"        ／�ｦ＼／�ｦ＼／＼／"	"   HO   �ｾ"	"    �ﾒ／"	"      �ｵ            CH3"	"      ＼�ｧ／＼／＼／"					"130/"						"METHANOL (130), ETHYL ACETATE , 1-CHLOROBUTANE (147)"	"130/147/"	"λmax = 237nm (130)"			"METHYL ESTER TMS ETHER : M/E 406(M+), 391, 375, 316, 295 (130)"		"130/"	"ヒト尋常性乾癬の皮部病変部に出現する(131)。 ウニの卵にも見出されている(130)  また，ウシ角膜(132) やラット肝(133) のミクロソームとアラキドン酸と反応さると生成し，P-450 の反応産物と考えられている。"	"131/130/132/133/"	"ウニの卵の成熟に関与する(130)。角膜の Na+，K+−ATPアーゼを阻害する(132)。ヒト多形核白血球を活性化する(134)"	"130/132/134/"		
"PR0048"	13.00	"[R-(Z,E,Z,Z)]-8-HYDROPEROXY-5,9,11,14-EICOSATETRAENOIC ACID"		"8(R)-HPETE"		"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"              OOH                                            (REF:135)"	"              �ﾂ            COOH"	"        ／�ｹ／＼／�ｦ＼／＼／"	"        �ｾ"	"        ＼／�ｦ＼／＼／＼"	"                        CH3"						"135/"						"ETHYL ACETAT ,METHANOL (135)"	"135/"	"λmax = 235.8nm (ε= 28,000)(135)"					"135/"	"サンゴの 8−リポキシゲナーゼによって作られ，プロスタノイド生合成の中間体と なる(136/137)"	"136/137/"				
"PR0049"	13.00	"[R-(Z,E,Z,Z)]-8-HYDROXY-5,9,11,14-EICOSATETRAENOIC ACID"		"8(R)-HETE"		"C20H32O3"	20.00	32.00	3.00	0.00	0.00	0.00	320.00	"              OH                                            (REF:135)"	"              �ﾂ            COOH"	"        ／�ｹ／＼／�ｦ＼／＼／"	"        �ｾ"	"        ＼／�ｦ＼／＼／＼"	"                        CH3"						"135/"			"8(S)-ISOMER METHYL ESTER : [α]22/D = -4.75(C=0.4 CHCl3)(148)"			"ETHYL ACETATE (135)"	"148/135/"	"METHYL ESTER : λmax = 235.8nm (ε= 28,000)(135)"		"8(S)-ISOMER,METHYL ESTER:1H-NMR(CDCl3)δ6.56(dd,J=14.5,11.1Hz,1H,10-CH), 6.00(brt,J=11.1, 9.7Hz, 1H, 11-CH), 5.72(dd,J=7.3, 14.5Hz, 1H, 9-CH), 5.59-5.16(m, 5H), 4.23(q,1H,8-CH), 3.71(s,3H,OCH3), 2.95(t,2H,13-CH), 2.35(t,4H,4,7-CH), 2.11(sextet,4H), 1.73("	"METHYL ESTER, TMS ETHER : M/E 265 (135 8(S)-ISOMER METHYL ESTER,TMS ETHER : M/E 406, 391, 316, 265, 243(148)"		"135/148/"			"ヒトデ卵の成熟に関連する(138)"	"138/"		
"PR0050"	13.00	"[R-(Z,Z,Z)]-12-HYDROXY-5,8,14-EICOSATRIENOIC ACID"				"C20H34O3"	20.00	34.00	3.00	0.00	0.00	0.00	322.00	"                                                            (REF:139)"	"                          COOH"	"        ／�ｦ＼／�ｦ＼／＼／"	"      ／"	"      ＼                    CH3"	"        ＼�ｽ／＼�ｧ／＼／＼／"	"            �ﾂ"	"            OH"				"139/"			"METHYL ESTER : [α]23/D = -3.0ﾟ(C=0.8, ACETONE)(149)"			"ETHYL ACETATE (139)"	"149/139/"	"共役ジエンやカルボニルの吸収を示さない。(139)"		"METHYL ESTER:1H-NMR(CDCl3)δ5.63-5.51(m, 1H), 5.47-5.28(m, 5H), 3.67(s, 3H), 3.67-3.57(m, 1H), 2.79(t, J=5.5Hz, 2H), .32(t, J=7.4Hz, 3H), 2.30-1.99(m, 6H),  1.76-1.49(m,6H), 1.40-1.23(m, 6H), 0.88(t, J=6.8Hz, 3H) (149)"""	"METHYL ESTER, TMS ETHER : M/E 393, 319, 297 (139)"		"139/149/"	"ウシ角膜上皮のミクロソームとアラキドン酸とを，NADPH の存在下で好気的に反応 させると生成する。(139)"	"139/"	"角膜損傷治癒に関係する。(139)"	"139/"		
"PR0051"	13.00	"(Z,Z,Z)-5,6-EPOXY-8,11,14-EICOSATRIENOIC ACID"	"5(6)OXIDO-8,11,14-EICOSATRIENOIC ACID"	"5,6-EET"		"C20H30O4"	20.00	30.00	3.00	0.00	0.00	0.00	318.00	"                  O                                       (REF:140)"	"                �ﾄ�ﾂ      COOH"	"        ／�ｦ＼／�ｼ＼／＼／"	"      ／"	"      ＼                    CH3"	"        ＼�ｧ／＼�ｧ／＼／＼／"						"140/"											"METHYL ESTER : M/E 334(M+), 316, 303, 283, 267, 233, 190, 176, 163,143(BASE PEAK)(140) METHYL ESTER : M/E 334(M+), 316, 303, 285, 245 (141)"		"140/141/"	"ラット(140)あるいはウサギ(141)の肝ミクロソームとアラキドン酸を反応させた時 に生成する。"	"140/141/"	"ソマトスタチン，インスリン，グルカゴンの分泌，血管拡張，細胞内カルシウム調 節(142)｡"	"142/"		
"PR0052"	13.00	"(Z,Z,Z)-8,9-EPOXY-5,11,14-EICOSATRIENOIC ACID"	"8(9)OXIDO-5,11,14-EICOSATRIENOIC ACID"	"8,9-EET"		"C20H30O3"	20.00	30.00	3.00	0.00	0.00	0.00	318.00	"          O                                               (REF:140)"	"          �ﾏ              COOH"	"        ／�ｼ＼／�ｦ＼／＼／"	"      ／"	"      ＼                    CH3"	"        ＼�ｧ／＼�ｧ／＼／＼／"						"140/"			"8(S),9(R)-EET METHYL ESTER : [α]23/D = +2.33(C=1, ACETONE)(150)"			"CHCl3 (151)"	"150/151/"			"1H-NMR(CDCl3) : δ5.70-5.08(m,6H), 3.06-2.65(m,4H), 2.62-1.04(COMPLEX m, 18H), 0.88(t, 3H)(151)"	"METHYL ESTER : M/E 334(M+), 316, 303, 290, 245, 193, 183, 175, 165 (141)"		"151/141/"	"ラット(140)あるいはウサギ(141)の肝ミクロソームとアラキドン酸を反応させた時 に生成する。ウサギ腎(143)，ヒト尿(144)から単離。"	"140/141/143/"	"腸動脈の拡張作用。(142)"	"142/"		
"PR0053"	13.00	"(Z,Z,Z)-11,12-EPOXY-5,8,14-EICOSATRIENOIC ACID"	"11(12)OXIDO-5,8,14-EICOSATRIENOIC ACID"	"11,12-EET"		"C20H30O3"	20.00	30.00	3.00	0.00	0.00	0.00	318.00	"                                                          (REF:140)"	"                          COOH"	"        ／�ｦ＼／�ｦ＼／＼／"	"      ／"	"      ＼                    CH3"	"        ＼�ｽ／＼�ｧ／＼／＼／"	"          �ﾆ"	"           O"				"140/"			"11(R),12(S)-EET METHYL ESTER : [α]23/D = +4.94(C=1.64,ACETONE)(150)  11(S),12(R)-EET METHYL ESTER : [α]24/D = -2.34ﾟ(C=0.66, CHCl3)(151)"				"150/151/"				"METHYL ESTER : M/E 340(M+), 322, 309, 227, 155 (141)"		"150/141/"	"ラット(140)あるいはウサギ(141)の肝ミクロソームとアラキドン酸を反応させた時 に生成する。"	"140/141/"	"腸動脈の拡張,膀胱のヴアソプレシン依存性水透過を阻害，細胞内カルシウム調節  (142)｡"	"142/"		
"PR0054"	13.00	"14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID"	"14(15)OXIDO-5,8,11-EICOSATRIENOIC ACID"	"14,15-EET"		"C20H30O3"	20.00	30.00	3.00	0.00	0.00	0.00	318.00	"                                                          (REF:140)"	"                          COOH"	"        ／�ｦ＼／�ｦ＼／＼／"	"      ／"	"      ＼                    CH3"	"        ＼�ｧ／＼�ｽ／＼／＼／"	"                �ﾆ"	"                 O"				"140/"			"14(R),15(S)-EET METHYL ESTER : [α]24/D = -2,75(C=0.70, CHCl3)14(S),15(R)-EET METHYL ESTER : [α]24/D = +2.78(C=0.82, CHCl3)(151)"				"151/"				"METHYL ESTER: M/E 334(M+), 316, 281, 263, 220, 161, 147, 119, 91(BASE)(140)METHYL ESTER: M/E 334(M+), 316, 303, 263, 245, 235, 234, 220, 119, 91(141)"		"140/141/"	"ラット(140)あるいはウサギ(141)の肝ミクロソームとアラキドン酸を反応させた時 に生成する。ウサギ腎(143)，ヒト尿(144)から単離。"	"140/141/143/144/"	"グルカゴン分泌，膀胱のヴァソプレシン依存性水透過を阻害，細胞内カルシウム調 節，血小板凝集阻害。(142)"	"142/"		
"PR0055"	13.00	"16-(3-ETHYLOXIRANYL)-[2α.(Z,Z,Z,Z),3α]-5,8,11,14-HEXADECATETRAENOIC ACID"	"17(R)(18S)OXIDO-5,8,11,14-EICOSATETRATENOIC ACID"	"17(18)EpETE"		"C20H28O3"	20.00	28.00	3.00	0.00	0.00	0.00	316.00	"                                                          (REF:152)"	"                          COOH"	"        ／�ｦ＼／�ｦ＼／＼／"	"      ／"	"      ＼"	"        ＼�ｧ／＼�ｧ／＼�ｽ�ｽ／＼"	"                      �ﾂ�ﾄ    CH3"	"                      O"				"152/"											"d,l-MIXTURE METHYL ESTER : M/E  303, 301, 285, 275, 273, 271, 260, 257,253, 245, 243, 231, 217, 213, 206, 199, 187, 180, 173, 159, 145, 131, 119, 117, 105, 93, 91(100%), 81, 79, 71, 67, 59, 57, 55(152)"		"152/"	"サル精嚢線ミクロソームと 5,8,11,14,17-エイコサペンタエン酸を反応させた時に 生成する。(145)"	"145/"				
"PR0056"	13.00	"7-[2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-5-OXO-3-CYCLOPENTEN-1(R)-YL]HEPTANOIC ACID  ((8R,12S,13E,15S)-15-HYDROXY-9-OXO-10,13-PROSTADIENOIC ACID)"	"PROSTAGLANDIN A1"	"PGA1"		"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"                                                              (REF:165)"	"         O               COOH"	"         �ｾ�ﾄ＼／＼／＼／"	"       ／�ｻ"	"       �ｸ�ｺ                CH3"	"           �ｸ�ｷ＼／＼／＼／"	"                 �ﾂ"	"                 OH"				"165/"	"42-44ﾟC(164)"		"ORD(H2O, C=0.0040g/ml) 256(+35.000゜), 220(-43.000゜)"			"ETHANOL,CHLOROFORM (165) METHANOL(166)"	"164/165/166/"	"λEtOH/MAX=217mμ(ε=11,650)(165)"	"νMAX(NUJOL) 3420, 2740, 2700, 2660, 2600, 1715, 1700, 1585, 1275, 1200,1180, 1020, 720cm-1 (165)"	"1H-NMR(CDCl3),TMS)δ 7.52(d,d,1H), 6.17(d,d,1H), 5.6(m,2H),4.1(m,1H,15-CH), 3.25(12H) (165)"	"M/E, 336(M+), 318(M-18), 300(M-36), 265(M-71), 247, 219, 190 (165)"	"ORD(H2O,C=0.0040g/100ml), 256(+35, 000ﾟ), 220(-43,000ﾟ)(166)"	"165/167/"	"ヒトの精液の中に見出されている(154)｡ PGE1が酸性下で分解して, 非酵素反応産物としてPGA1を生じるので(161), 組織からの抽出の過程での産物である可能性に注意を要する。"	"154/161/"	"ヒト子宮筋の弛緩(153/158), ラットとイヌの血圧降下作用(058)が記載されている｡"	"153/158/"		
"PR0057"	13.00	"7-[2-(3(S)-HYDROXY-1(E)-OCTENYL)-5-OXO-1-CYCLOPENTEN-1-YL]HEPTANOIC ACID/((13E,15S)-15-HYDROXY-9-OXO-8(12),13-PROSTADIENOIC ACID)"	"PROSTAGLANDIN B1"	"PGB1"		"C20H32O4"	20.00	32.00	4.00	0.00	0.00	0.00	336.00	"                                                              (REF:166)"	"         O                COOH"	"         �ｾ／＼／＼／＼／"	"       ／�ｼ�ｾ"	"       ＼  �ｾ               CH3"	"         �ｼ＼�ｷ＼／＼／＼／"	"                 �ﾂ"	"                 OH"				"166/"	"70-71ﾟC(164)"						"164/"	"λMAX=278mμ(ε=28,650)(168)"	"νMAX   1725, 1668, 1635, 1596, 970 cm-1 (169)"	"1H-NMR ;δ  6.87(d,J=16Hz,1H,13-CH), 6.25(d,d,J=16.6Hz,1H,14-CH),4.38(1H,15-CH) (170)"	"METHYL ESTER: M/E  350(M+), 332, 319, 301, 251, 219 (167)"		"168/169/170/167/"	"ヒト精液に含まれる(154)。"	"154/"				
"PR0058"	13.00	"7-[3(R)-HYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)-5-OXOCYCLOPENTAN-1(R)-YL]-HEPTANOIC ACID/((8R,11R,12R,13E,15S)-11,15-DIHYDROXY-9-OXO-13-PROSTENOIC ACID)"	"PROSTAGLANDIN E1"	"PGE1"		"C20H34O5"	20.00	34.00	5.00	0.00	0.00	0.00	354.00	"                                                              (REF:171)"	"         O               COOH"	"         �ｾ�ﾄ＼／＼／＼／"	"       ／�ｻ"	"       ＼�ｺ                CH3"	"       �ﾄ  �ﾖ�ｷ＼／＼／＼／"	"     HO          �ﾂ"	"                 OH"				"171/"	"115-117ﾟC (171)"		"[α]/578 = -61.6ﾟ C=0.56 THF (172)"			"ETHYL ETHER, ETHYL ACETATE (171) MeOH(167),THF (172)"	"171/172/167/"		"METHYL ESTER: ν 1726, 1717sh, 1699, 980 cm-1 (173)"	"1H-NMR(CDCl3+DMSO-d6,TMS): δ 5.70-5.51(m,2H),4.14-3.86(m,2H),2.72(d,d,1H).13C-NMR(CHCl3-CH3OH,TMS):δ 215.2(C-9),176.7(C-1),136.6(C-14),131.9(C-13),72.9(C-15),71.6(C-11),54.6(C-8),54.2(C-12),45.9(C-10),36.9(C-16),33.8(C-2),31.5(C-18),29.0(C-4),28.6(C-5)"	"M/E  332(171)"		"173/171/"	"初期の研究で, ヒトやヒツジの精液, ヒツジ精嚢腺, ヒトの月経血・羊水・子宮内 膜・臍帯・胎盤血管・脱落膜, カエル脊髄, ラット副腎, ヒトとウシ胸腺, カエル 腸, ラット脂肪, ヒト横隔膜神経に見出されている(153/154/155/156/157)｡ 分布に関しては文献162を参照されたい"	"153/154/155/156/157/162/"	"一般的にはPGE2と同じ生物活性を示すと考えられており, PGE2の活性に対するPGE1 の比が文献158/159に, また, PGE1の活性をPGF1αとPGF2αの活性と比較した値が文献153 に記載されている｡ ただし, 血小板凝集に関しては, PGE1には阻害作用があるのに，PGE2はむしろ促進作用がある。"	"158/159/153/160/162/"		
"PR0059"	13.00	"7-[3(R),5(S)-DIHYDROXY-2(R)-(3(S)-HYDROXY-1(E)-OCTENYL)CYCLOPENTAN-1(R)-YL]-HEPTANOIC ACID/((8R,9S,11R,13E,15S)-9,11,15-TRIHYDROXYPROST-13-ENOIC ACID)"	"PROSTAGLANDIN F1α"	"PGF1α"		"C20H36O5"	20.00	36.00	5.00	0.00	0.00	0.00	356.00	"                                                              (REF:175)"	"     HO                  COOH"	"       �ﾅ  �ﾄ＼／＼／＼／"	"       ／�ｻ"	"       ＼�ｺ                CH3"	"       �ﾄ  �ﾖ�ｷ＼／＼／＼／"	"     HO          �ﾂ"	"                 OH"				"175/"	"102-103ﾟC (175)"		"[α]25/D(EtOH) = +30ﾟ(165)"			"ETHYL ETHER, ETHYL ACETATE, METHANOL(175)ETHANOL (165)"	"175/165/"		"d,l-PGF1α : ν(KBr) ; 3330, 1716, 967 cm-1 (176)"	"1H-NMR(ACETONE-d6,TMS): δ 5.50(2H,13-,14-CH), 3.75-4.3(m,3H),0.88(t,3H) (164)"	"M/E  356(M+), 338, 320 (164)"		"176/164/"	"ヒト精液に３μg/ml存在し, ヒツジの精嚢腺と肺に存在するとの報告がある(155)。文献157の記載によると,PGF2αが1-100ng/g湿重量で存在する多くの組織に, PGF1αは探知されなかったという｡ 文献154では, ヒトやヒツジの精液, ヒツジ精嚢, ヒトの羊水, 臍帯, 胎盤血管, 脱落"	"155/157/154/"	"文献153によると, 種々の動物の消化管の平滑筋収縮に関しては, PGF1αはPGF2αに比べて10倍以上も活性が低い｡ 文献158に種々のPGEおよびPGFとの活性の比較がまとめてある｡"	"153/158/"		
"PR0060"	13.00	"7-[3(R)-HYDROXY-2(R)-(3(S)-HYDROXYOCTA-1(E),5(Z)-DIENYL)-5-OXO-CYCLOPENTAN-1(R)-YL]-5(Z)-HEPTENOIC ACID/((5Z,8R,11R,12R,13E,15S,17Z)-11,15-DIHYDROXY-9-OXO-5,13,17-PROSTATRIENOIC ACID"	"PROSTAGLANDIN E3"	"PGE3"		"C20H30O5"	20.00	30.00	5.00	0.00	0.00	0.00	350.00	"                                                              (REF:177)"	"         O"	"         �ｾ�ﾄ＼�ｧ／＼／＼"	"       ／�ｻ              COOH"	"       ＼�ｺ"	"       �ﾄ  �ﾖ�ｷ＼／＼�ｧ／＼"	"     HO          �ﾂ        CH3"	"                 OH"				"177/"	"84.5-85.5ﾟC (178)"		"[α]24/D = -48.9ﾟ(C=1.2,THF)(179)"			"TETRAHYDROFURAN (179)"	"178/179/"			"METHYL ESTER:1H-NMR(CDCl3) δ 5.8-5.5(m,2H,13,14-CH),5.5-5.2(m,4H,5,6,17,18-CH), 4.4-3.8(m,2H,11,15-CH),0.95(t,3H,20-CH) (180)"	"METHYL ESTER : M/E, 346(M-18), 328(M-18x2), 315, 297, 277, 259, 188 (177)"		"180/177/"	"ヒトの精液に5.5μg/ml含まれ, PGE1とPGE2の値の1/5程度である(153)｡ その他にヒツジの精液と精嚢腺に見出される(154)｡"	"153/154/"	"文献158の記載によると, 種々の活性はPGE1に比べて1/5〜1/2程度の強さである｡"	"158/"		
"PR0061"	13.00	"7-[3(R),5(S)-DIHYDROXY-2(R)-(3(S)-HYDROXYOCTA-1(E),5(Z)-DIENYL)CYCLOPENTAN-1(R)-YL]-5(Z)-HEPTENOIC ACID/((5Z,8R,9S,11R,12R,13E,15S,17Z)-9,11,15-TRIHYDROXYPROSTA-5,13,17-TRIENOIC ACID"	"PROSTAGLANDIN F3α"	"PGF3α"		"C20H32O5"	20.00	32.00	5.00	0.00	0.00	0.00	352.00	"                                                              (REF:   )"	"     HO"	"       �ﾅ  �ﾄ＼�ｧ／＼／＼"	"       ／�ｻ              COOH"	"       ＼�ｺ"	"       �ﾄ  �ﾖ�ｷ＼／＼�ｧ／＼"	"     HO          �ﾂ        CH3"	"                 OH"							"[α]26/D = +29.6ﾟ(C=0.54,THF) (179)"			"TETRAHYDROFURAN (179)"	"179/"				"TRI-TMS ETHER, METHYL ESTER,AMMONIA CI : M/E, 600(M+18), 585, 583(M+1),510, 493, 420, 403 (181)"		"181/"	"ウシの肺に見出されている(153/154/155)｡"	"153/154/155/"				
"PR0062"	13.00	"7-[TETRAHYDRO-4(S),6-DIHYDROXY-2(R)-(3(S)-HYDROXY-1(E),5(Z)-OCTADIENYL)-2H-PYRAN-3(S)-YL]-5(Z)-HEPTENOIC ACID"	"THROMBOXANE B3"	"TXB3"		"C20H32O6"	20.00	32.00	6.00	0.00	0.00	0.00	368.00	"                                                              (REF:181)"	"       HO"	"         �ﾂ"	"       ／＼�ﾄ＼�ｧ／＼／＼"	"     �ｶ  �ｶ              COOH"	"   HO�ﾝ＼／�ﾖ�ｷ＼／＼�ｧ／＼"	"        O        �ﾂ        CH3"	"                 OH"				"181/"						"ETHYL ETHER (182)THYL ACETATE, CHLOROFORM (183)"	"182/183/"		"FILM: ν 3392, 3010, 2932, 1713, 1407, 1363, 1231, 1154, 1104, 1024,973, 895 cm-1 (183)"	"1H-NMR(CDCl3,TMS):δ 5.85(dd,J=17.5,6.3Hz,1H,14-CH),5.71(dd,J=17.5,7.5Hz,1H,13-CH),5.55(td,J=20.0,12.5Hz,1H,18-CH),5.48-5.31(m,4H,5,6,11,17-CH),4.41(dd,J=12.5,7.5Hz,1H,12-CH),4.23(dt,J=12.5,6.3Hz,1H,15-CH),4.08(m,1H,9-CH),2.40-2.24(m,4H,4,16-CH),2.18-1.9"	"FAB : M/E, 351(M+1-H2O), 333, 315, 307 (183)"		"183/"	"ヒト血小板で5,8,11,14,17-エイコサペンタエン酸から作られることが報告されている(182)"	"182/"				
"PR0063"	13.00	"5(S),12(R)-DIHYDROXY-6(Z),8(E),10(E),14(Z),17(Z)-EICOSAPENTAENOIC ACID"	"LEUKOTRIENE B5"	"LTB5"		"C20H30O4"	20.00	30.00	4.00	0.00	0.00	0.00	334.00	"                                                              (REF:   )"			"       ／＼／�ｹ／�ｹ／�ｦ＼／＼／＼"	"       �ｾ  �ﾂ            �ﾂ      COOH"	"       �ｾ  OH    CH3     OH"	"       ＼／�ｦ＼／"											"METHANOL (184)"	"184/"	"λMAX 260sh, 270, 290sh nm (185)"		"METHYL ESTER DIACETATE;1H-NMR(BENZEN-d6,270MHz):6.79(dd,J=11.53,14.83Hz,1H,8-CH),6.34(dd,J=10.55,14.83Hz,1H,10-CH),6.09(dd,J=10.87,14.83Hz,1H,H-9),6.03(t,J=11.53Hz,7-CH),5.90(dt,J=Ca.9.5,11Hz,5-CH),5.63(dd,J=6.92,14.82Hz,11-CH),5.60-5.38(m,5H,12,14,15,17"	"METHYL ESTER TRIMETHYLSILYL ETHER  M/E, 492(M+), 477, 461, 402, 391, 383,293, 267, 229, 217, 203 (185)"		"185/184/"	"ヒトの好中球にほとんど探知されないが, エイコサペンタエン酸を摂取したヒトで はロイコトリエンB5が見出される(188)｡"	"188/"	"ラット好中球の凝集, ヒト多形核白血球の遊走, ヒト多形核白血球からのリソゾー ム酵素の遊離, ブラジキニンによる血漿漏出の促進などの生物活性は, ロイコトリ エンB4の1/30以下である(186)｡ ひと好中球細胞質のカルシウム濃度上昇作用は, ロイコトリエンB5(ED50=５nM)はロ"	"186/187/"		
"PR0064"	13.00	"7-[2(R)-(3(S),7-DIHYDROXY-1(E)-OCTENYL)-5-OXO-3-CYCLOPENTEN-1(R)-YL]-5(Z)-HEPTENOIC ACID/(15(S),19-DIHYDROXY-9-OXO-8(12),13-TRANS-PROSTADIENOIC ACID)"	"19-HYDROXY-PROSTAGLANDIN A2"	"19-HYDROXY-PGA2"		"C20H30O4"	20.00	30.00	5.00	0.00	0.00	0.00	350.00	"                                                              (REF:169)"	"         O"	"         �ｾ�ﾄ＼�ｧ／＼／＼"	"       ／�ｻ              COOH"	"       �ｸ�ｺ                CH3"	"           �ﾖ�ｴ＼／＼／＼／"	"                 �ﾂ      �ｯ"	"                 OH      OH"				"169/"						"ETHYL ETHER, CHLOROFORM, ETHANOL(169)"	"169/"	"λMAX EtOH  217 nm(ε= 〜10,000) (169)"	" 5.87, 6.30, 10.3μ (169)"	"1H-NMR: δ 5.75-5.50(m,2H,13,14-CH), 5.50-5.25(m,2H,5,6-CH),1.15(d,3H,20-CH) (169)"	"METHYL ESTER : M/E  364(M+), 246, 328, 315 (169)"		"169/"	"ヒト精液中に存在する(153)｡ 19-HYDROXY-PGE2より生じた人為産物とされている(163)｡"	"153/163/"	"ヒト子宮筋収縮を阻害する(161)｡"	"161/"		
"PR0065"	13.00	"7-[2-(3(S),7-DIHYDROXY-1(E)-OCTENYL)-5-OXO-1-CYCLOPENTEN-1-YL]-5(Z)-HEPTENOIC ACID/(15(S),19-DIHYDROXY-9-OXO-5-CIS-8(12),13-TRANS-PROSTATRIENOIC ACID)"	"19-HYDROXY-PROSTAGLANDIN B2"	"19-HYDROXY-PGB2"		"C20H30O5"	20.00	30.00	5.00	0.00	0.00	0.00	350.00	"                                                              (REF:169)"	"      O"	"       �ｸ�ｽ�ﾄ＼�ｧ／＼／＼"	"       ／�ｳ              COOH"	"       ＼�ｳ                CH3"	"         �ｼ＼�ｴ＼／＼／＼／"	"                 �ﾂ      �ｯ"	"                 OH      OH"				"169/"						"ETHANOL (169)"	"169/"	"λMAX EtOH  278 nm(ε= 〜20,000) (169)"	" 5.92, 6.09, 6.26, 10.3μ (169)"				"169/"	"ヒト精液中に存在する(153)｡ 19-HYDROXY-PGE2より生じた人為産物とされている(163)｡"	"153/163/"	"ヒト子宮筋収縮を阻害する(161)｡"	"161/"		
"PR0066"	13.00	"11-[(2-AMINO-2-CARBOXYETHYL)THIO]-12-HYDROXY-5,7,9-HEXADECATRIENEDIOIC ACID OR 5-HYDROXY-6-CYSTEIN-S-YL-7,9,11-HEXADECATRIENEDIOIC ACID"	"16-CARBOXY-17,18,19,20-TETRANOR-14,15-DIHYDROLEUKOTRIENE E4"			"C19H29O7NS"	19.00	29.00	7.00	1.00	0.00	1.00	415.00	"                        OH                          (REF:009/012/013)"	"                        �ﾑ      COOH"	"          �ｴ＼�ｴ＼�ｴ＼／＼／＼／"	"          �ｵ          �ﾂ"	"        ／            S      NH2"	"        �ｵ             ＼  �ﾄ"	"        ＼               �ｼ＼"	"          COOH               COOH"				"009/012/013/"								"λMAX 279nm (MeOH) (009)"		"1H-NMR(300MHz,CD3OD), 3.43(dd,1H,SCH2) (009)"			"009/"	"ホ乳類の尿, 胆汁LEUKOTRIENE E4 のβ酸化物"					
"PR0067"	13.00	"11-[(2-N-ACETYL-2-CARBOXYETHYL)THIO]-12-HYDROXY-5,7,9-HEXADECATRIENEDIOIC ACID OR 5-HYDROXY-6-(N-ACETYLCYSTEIN-S-YL)-7,9,11-HEXADECATRIENEDIOIC ACID"	"16-CARBOXY-17,18,19,20-TETRANOR-14,15-DIHYDRO-N-ACETYL-LTE4"			"C21H31O8NS"	21.00	31.00	8.00	1.00	0.00	1.00	457.00	"                        OH                          (REF:009/011)"	"                        �ﾑ      COOH"	"          �ｴ＼�ｴ＼�ｴ＼／＼／＼／"	"          �ｵ          �ﾂ"	"        ／            S      NH―C―CH3"	"        �ｵ             ＼  �ﾄ    �ｾ"	"        ＼               �ｼ＼    O"	"          COOH               COOH"				"009/011/"								"λMAX 279nm (MeOH) (009/011)"		"1H-NMR(300MHz,CD3OD)  δ2.11(s,3H,COCH3),2.76(dd,1H,SCH2),2.93(dd,1H,SCH2), 3.86,4.38(m,1H) (009)"	"FAB(NEG,GLYCEROL) M/E 456(M-H+), [M-H]- 456,1678 (009/011)"		"009/011/"	"ねずみの胆汁 (010)  LEUKOTRIENE E4 のβ酸化物"	"010/"				
"PR0068"	13.00	"13-[(2-AMINO-2-CARBOXYETHYL)THIO]-14-HYDROXY-4,7,9,11-OCTADECATETRAENEDIOIC ACID OR 5-HYDROXY-6-CYSTEIN-S-YL-7,9,11,14-OCTADECATETRAENEDIOIC ACID"	"18-CARBOXYDINORLEUKOTRIENE E4"			"C21H31O7NS"	21.00	31.00	7.00	1.00	0.00	1.00	441.00	"                        OH                          (REF:009/012/013)"	"                        �ﾑ      COOH"	"          �ｴ＼�ｴ＼�ｴ＼／＼／＼／"	"          �ｵ          �ﾂ"	"        ／            S      NH2"	"        �ｾ             ＼  �ﾄ"	"        ＼／＼           �ｼ＼"	"              COOH           COOH"				"009/012/013/"								"λMAX 280nm (MeOH) (009)"		"1H-NMR(300MHz,CD3OD)  δ3.75(m,1H),5.4(m,3H,H-12,14,15),6.25(m,2H,H-8,9),6.6(t,1H,H-10) (009)"			"009/"	"LTE4 と LTC4 代謝物 (010)"	"010/"				
"PR0069"	13.00	"13-[(2-N-ACETYL-2-CARBOXYETHYL)THIO]-14-HYDROXY-4,7,9,11-OCTADECATETRAENEDIOIC ACID OR (5S,6R)-5-HYDROXY-6-(N-ACETYLCYSTEIN-S-YL)-7,9-(E),11,14(Z)-OCTADECATETRAENEDIOIC ACID"	"18-CARBOXY-19,20-DINOR-N-ACETYL-LTE4"			"C23H33O8NS"	23.00	33.00	8.00	1.00	0.00	1.00	483.00	"                        OH                          (REF:009/011)"	"                        �ﾑ      COOH"	"          �ｴ＼�ｴ＼�ｴ＼／＼／＼／"	"          �ｵ          �ﾂ"	"        ／            S      NH―C―CH3"	"        �ｾ             ＼  �ﾄ    �ｾ"	"        ＼／＼           �ｼ＼    O"	"              COOH           COOH"				"009/011/"								"λMAX 280nm (MeOH) (009/011)"		"1H-NMR(300MHz,CD3OD)  1.99(s,3H,Nac),2.77(dd,1H,SCH) (009)"	"M/Z 482,1764 (011)"		"009/011/"	"LTE4 と LTC4 代謝物 (010)"	"010/"				
"PR0070"	13.00	"9-[(2-AMINO-2-CARBOXYETHYL)THIO]-10-HYDROXY-3,5,7-TETRADECATRIENEDIOIC ACID"	"14-CARBOXYHEXANORLEUKOTRIENE E3"			"C17H25O7NS"	17.00	25.00	7.00	1.00	0.00	1.00	387.00	"                        OH                          (REF:012/013)"	"                        �ﾑ      COOH"	"          �ｴ＼�ｴ＼�ｴ＼／＼／＼／"	"          �ｵ          �ﾂ"	"          ＼          S      NH2"	"            COOH       ＼  �ﾄ"	"                         �ｼ＼"	"                             COOH"				"012/013/"														"ヒト(L-00016) LEUKOTRIENE E4 の尿の代謝物"